Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01236040 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 521
- Enrollment target
NCT01236040: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT01236040 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 521 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (768% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01236040, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 521 participants
- Enrollment target
Study Summary
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
Interventions
- OTHER Placebo
- BIOLOGICAL GSK Biologicals' investigational vaccine GSK2590066A
- BIOLOGICAL GSK Biologicals' investigational vaccine GSK2592984A
- BIOLOGICAL GSK Biologicals' investigational vaccine GSK2340274A
- BIOLOGICAL GSK Biologicals' investigational vaccine GSK2340273A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 521 participants |
| Start Date | 2010-11-29 |
| Est. Completion | 2012-08-20 |
| Phase | Phase 1 |
What the finished NCT01236040 record still lists
NCT01236040 is an interventional study that assigns participants to a tested intervention. The registered 521 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (768% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01236040 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01236040 about?
NCT01236040 is a clinical study titled "Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old". This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
What is the current status of trial NCT01236040?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 521 participants. The study started on 2010-11-29. Estimated completion is 2012-08-20.
What interventions are being tested in trial NCT01236040?
The interventions under investigation include: Placebo (OTHER), GSK Biologicals' investigational vaccine GSK2590066A (BIOLOGICAL), GSK Biologicals' investigational vaccine GSK2592984A (BIOLOGICAL), GSK Biologicals' investigational vaccine GSK2340274A (BIOLOGICAL), GSK Biologicals' investigational vaccine GSK2340273A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01236040?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01236040's enrollment target sits among peer trials
521 40th of 2000 higher than 1,961 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
- NCT06894212 · 522 participants · Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI